Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 13INDUSTRY 9NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 8Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 5Ovarian Neoplasms 4Endometrial Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Leukemia, Myeloid, Acute 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Breast Neoplasms 3Urogenital Neoplasms 2Sezary Syndrome 2Pancreatic Neoplasms 2Neoplasms 2Mycosis Fungoides 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Glioma 2Colorectal Neoplasms 2Carcinosarcoma 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Biliary Tract Neoplasms 2

Interventions

Cyclophosphamide 31Rituximab 22Vincristine 19Doxorubicin 17Filgrastim 15Prednisone 14Peripheral Blood Stem Cell Transplantation 14Etoposide 13Cytarabine 12Magnetic Resonance Spectroscopy 10fludarabine phosphate 9Radiotherapy 9Bortezomib 9Biopsy 9Cyclosporine 8Specimen Handling 7Methotrexate 7Dexamethasone 7X-Rays 6Vorinostat 6Phantoms, Imaging 6Leucovorin 6Lenalidomide 6tanespimycin 5sargramostim 5fludarabine 5bryostatin 1 5aldesleukin 5Nuclear Medicine Department, Hospital 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Lymphoma, Non-Hodgkin × pembrolizumab × Clear all
NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

Phase 1 Completed
58 enrolled 17 charts
DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT03255018 2023-11-28

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled 21 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡